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doi:10.1016/j.jtcvs.2003.11.0251350 The Journal of Thoracic and CardBackground: The National Emphysema Treatment Trial, a randomized trial com-
paring lung volume reduction surgery with medical therapy for severe emphysema,
included randomized and nonrandomized comparisons of the median sternotomy
and video-assisted thoracoscopic approaches for lung volume reduction surgery.
Methods: Lung volume reduction surgery was performed by median sternotomy
only at 8 centers and video-assisted thoracoscopy only at 3 centers; 6 centers
randomized the approach to lung volume reduction surgery. Mortality, morbidity,
functional status, and costs were assessed.
Results: In the nonrandomized comparison, 359 patients received lung volume
reduction surgery by median sternotomy, and 152 patients received lung volume
reduction surgery by video-assisted thoracoscopy. The 90-day mortality was 5.9%
for median sternotomy and 4.6% for video-assisted thoracoscopy (P .67). Overall
mortality was 0.08 deaths per person-year for median sternotomy and 0.10 deaths
per person-year for video-assisted thoracoscopy (video-assisted thoracoscopy-me-
dian sternotomy risk ratio, 1.18; P  .42). Complication rates were low and not
statistically different for the 2 approaches. The median hospital length of stay was
longer for median sternotomy than for video-assisted thoracoscopy (10 vs 9 days; P
 .01). By 30 days after surgery, 70.5% of median sternotomy patients and 80.9%
of video-assisted thoracoscopy patients were living independently (P  .02). Func-
tional outcomes were similar for median sternotomy and video-assisted thoracos-
copy at 12 and 24 months. Costs for the operation and the associated hospital stay
and costs in the 6 months after surgery were both less for video-assisted thoracos-
copy than for median sternotomy (P .01 in both cases). Similar results were noted
for the randomized comparison.
Conclusions: Morbidity and mortality were comparable after lung volume reduction
surgery by video-assisted thoracoscopy or median sternotomy, as were functional
results. The video-assisted thoracoscopic approach to lung volume reduction sur-
gery allowed earlier recovery at a lower cost than median sternotomy.
The optimal surgical approach for lung volume reduction surgery(LVRS) for advanced bilateral emphysema is unknown. Case seriesand early randomized trials have demonstrated the superiority ofstapled over laser resection1 and of bilateral over unilateral opera-tions.2 Case series support the use of either median sternotomy (MS)or video-assisted thoracoscopic (VATS) approaches.1-8 However,
there are no data that directly compare the functional outcomes or longer-term
results from these 2 approaches.
The National Emphysema Treatment Trial (NETT) was designed to compare the
safety, efficacy, patient selection, and cost-effectiveness of LVRS with those of
medical therapy for severe emphysema.9 Compared with medical management,
LVRS produced a significant improvement in function for patients with upper lobe
iovascular Surgery ● May 2004
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with upper lobe emphysema and a low baseline exercise
capacity.10 A secondary goal of the NETT was to compare
mortality, morbidity, and functional outcomes from the MS
and VATS approaches to LVRS. These findings are re-
ported in this article.
Materials and Methods
The design and methods of the NETT have been described previ-
ously9 and are summarized below.
Trial Protocol
After completion of pulmonary rehabilitation, patients with bilat-
eral severe emphysema judged suitable for LVRS were random-
ized in a 1:1 ratio to a program of continued medical therapy or
medical therapy plus LVRS. Eight clinical centers performed
LVRS by MS only and 3 by VATS only. Six centers performed
both VATS and MS, and patients at those centers were randomized
between the 2 approaches in a 1:1 ratio. Twenty-four surgeons
provided LVRS in NETT. At sites that provided both approaches
to LVRS, some surgeons performed both approaches. Some sites
that provided only 1 type of LVRS had more than 1 NETT
surgeon. Patients underwent bilateral stapled wedge resection
through MS or VATS; the goal was to resect 20% to 35% of each
lung, targeting the most diseased areas. Use of buttressing material
was at the discretion of the surgeon. The trial protocol was ap-
proved by the institutional review board of each center, and all
patients signed informed consent statements.
Outcomes
Outcomes included mortality, complications, hospital stay param-
eters (need for intensive care unit [ICU] care, need for mechanical
ventilation, and length of stay), status at initial hospital discharge
or 30 days after surgery, spirometry, exercise tolerance (assessed
by cycle ergometry and distance walked in 6 minutes), quality of
life, dyspnea, and costs. Respiratory disease-specific quality of life
was assessed by the St George’s Respiratory questionnaire,11 with
scores ranging from 0 to 100; lower scores indicate less dyspnea.
General quality of life was assessed by the Quality of Well-Being
Scale,12 with scores ranging from 0 (death) to 1 (ideal). Changes
in functional outcomes and quality of life were evaluated at 12 and
24 months after randomization.
Statistical Analysis
Two analyses of the MS versus VATS data are presented in this
article. In the nonrandomized comparison, the pooled MS group
(data from 14 centers) was compared with the pooled VATS group
(data from 9 centers). In the randomized comparison, the MS and
VATS groups at the 6 centers that randomized between MS and
VATS were compared. In the tables that follow, data are presented
for the nonrandomized comparison, and P values are shown for
both comparisons. Baseline characteristics were compared by us-
ing 2-sample t tests for continuous variables and Fisher exact
tests13 for categorical variables. The proportions of patients in each
treatment group who died or had complications were compared by
using Fisher exact or Freeman-Halton tests,14 depending on the
number of categories. The risk ratio for death was estimated on the
The Journal of Thoracicbasis of the overall mortality in each group after a mean of 31.9
months of follow-up.15 Mortality was measured from the date of
operation. Identification of subgroups of patients with differential
mortality was performed with logistic regression analyses and a set
of baseline prognostic factors, as described previously.10 Length of
hospital stay was derived from Medicare claims data; the length-
of-stay data include stays that ended in death in the hospital, as
well as discharge from the hospital. Changes from baseline in
functional outcome were grouped into 10 to 12 categories ranked
in order from greatest benefit to greatest deterioration, with death
the worst outcome and missing data the next worst. The distribu-
tions of categories of change were compared by using the Wil-
coxon rank sum test.13 Costs for the operation and associated
hospital stay and the total costs (medical and nonmedical) for the
6 months from the date of operation were collected and valued as
previously described.16 For the 6-month analysis, mean costs were
estimated with the nonparametric Kaplan-Meier sample average
estimator.17 This estimator sums monthly expected costs, where
the expected costs for a month are the product of the Kaplan-Meier
probability of surviving to the start of a month and the mean cost
among survivors over that month. Mean costs for MS versus
VATS derived from the Kaplan-Meier sample average estimator
method were then compared by using 2-sample t tests. Median
costs for each group were also derived and compared by using the
Wilcoxon rank sum test. All reported P values are based on 2-sided
tests.
Results
Study Patients
Between January 1998 and July 2002, 1218 patients were
randomized in NETT (610 to medical treatment and 608 to
LVRS). Interim analysis identified a subgroup of 140 pa-
tients (with a forced expiratory volume in 1 second 20%
of predicted and either a homogeneous pattern of emphy-
sema or a diffusing capacity of the lung for carbon monox-
ide of 20% predicted) at high risk for mortality after
LVRS and with little chance of benefit from the operation.18
Patients who met these criteria were subsequently excluded
from enrollment and were excluded from this analysis.
Among the remaining 538 patients randomized to LVRS, 20
patients refused an operation and 7 patients were judged
unsuitable for an operation after randomization, leaving 511
patients for analysis. The operation was performed via MS
in 359 patients and via VATS in 152 patients. Baseline
characteristics of these 511 patients are shown in Table 1.
The MS and VATS groups were similar except for a larger
proportion of patients with heterogeneous emphysema in
the MS group compared with the VATS group (61% vs
51%, respectively; P  .04; Table 1). When the analysis
was restricted to the centers that randomized patients to both
approaches, the MS group (77 patients) and VATS group
(71 patients) were comparable on all characteristics.
LVRS Procedure
Deviations from the surgical protocol (unilateral operation
or bilateral operation performed in 2 sessions) occurred in 4
and Cardiovascular Surgery ● Volume 127, Number 5 1351
General Thoracic Surgery National Emphysema Treatment Trial Research Group
G
TSMS patients and 8 VATS patients because of intraoperative
factors. Table 2 compares features of the LVRS procedures
performed with the MS and VATS approaches. The sur-
geons’ estimates of the percentage of lung resected by MS
were greater than their estimates of the percentage of lung
resected by VATS; however, the grams of lung parenchyma
resected by MS and VATS were not statistically different.
When the analysis was restricted to the centers that random-
ized patients to MS and VATS, no differences were ob-
served in the estimates of lung resected or in the grams of
TABLE 1. Characteristics of patients at baseline* (n 511)
Characteristic
Median
sternotomy
(n  359)
VATS
(n  152)
Age at randomization (y) 67.3 6.0 66.3 6.7
Sex, no (%)
Female 154 (43) 65 (43)
Male 205 (57) 87 (57)
Emphysema distribution on CT, no
(%)
Predominantly upper lobe 231 (64) 101 (66)
Predominantly non–upper lobe 128 (36) 51 (34)
Heterogeneous† 218 (61) 77 (51)
Homogeneous† 141 (39) 75 (49)
Maximal workload (W) 41.4 21.5 38.2 21.2
FEV1 after BD use (% of predicted) 27.9 6.6 28.6 7.1
TLC after BD use (% of predicted) 127.2 15.0 127.6 15.3
RV after BD use (% of predicted) 212.2 44.5 219.6 47.7
DLCO (% of predicted) 29.5 9.2 28.4 9.6
PaO2 (mm Hg) 64.6 10.3 66.6 11.2
PaCO2 (mm Hg) 42.8 5.5 42.8 6.0
St George’s Respiratory total score‡ 52.0 12.8 53.1 12.6
UCSD Shortness of Breath total
score§
60.5 18.7 60.9 17.6
Quality of Well-Being Scale average
daily score
0.57 0.11 0.59 0.12
CT, Computed tomography; BD, bronchodilator; FEV1, forced expiratory
volume in 1 s; TLC, total lung capacity; RV, residual volume; DLCO, diffusing
capacity of lung for carbon monoxide; PaO2, partial pressure of arterial
oxygen; PaCO2, partial pressure of arterial carbon dioxide; VATS, video-
assisted thoracoscopic surgery; UCSD, University of California-San Diego.
*Baseline measurements were obtained after rehabilitation and before
randomization except for DLCO, which was obtained before rehabilitation
and before randomization. Plus-minus values are mean  SD.
†Emphysema distribution was based on scores assigned subjectively to
each of 3 lung zones in each lung. P value for homogeneity  .04.
‡The St George Respiratory Questionnaire is a 51-item questionnaire
completed by the patient with regard to respiratory symptoms, in which the
total score ranges from 0 to 100 and lower scores indicate fewer respi-
ratory symptoms.
§The UCSD Shortness of Breath Questionnaire is a 24-item questionnaire
completed by the patient with regard to shortness of breath, in which the
total score ranges from 0 to 120 and lower scores indicate less shortness
of breath.
The Quality of Well-Being Scale is a 77-item questionnaire completed by
the patient with regard to quality of life. The average daily total score
ranges from 0 to 1, and higher scores indicate better quality of life.tissue resected.
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There were no intraoperative deaths in either treatment
group. The 30-day mortality rate was 2.8% for MS and
2.0% for VATS (P  .76), whereas the 90-day mortality
rate was 5.9% for MS and 4.6% for VATS (P  .67).
Similar results were observed when the analysis was re-
stricted to the centers that randomized patients to both MS
and VATS. During follow-up (mean, 31.9 months), 79 MS
patients and 39 VATS patients died. The overall mortality
rate was 0.08 deaths per person-year for MS patients and
0.10 deaths per person-year for VATS patients (risk ratio for
death in the VATS group, 1.18; P  .42). No predictors of
differential mortality by approach were identified.
Intraoperative Experience
There was no difference between the MS and VATS groups
in mean blood loss (138.0 vs 127.4 mL, respectively; P 
.55) or need for transfusion (3.1% vs 3.3%; P .99), but the
mean operating time was 21.7 minutes shorter for MS than
for VATS (105.0 vs 126.7 minutes; P  .001). When the
analysis was restricted to the centers that randomized pa-
tients to MS and VATS, the mean operating time was 8.8
minutes shorter for MS than for VATS, but the difference
was not statistically significant (P  .30).
A total of 93.0% of the MS patients and 86.2% of the
VATS patients had no intraoperative complications (P 
.02; Table 3). Hypoxemia was the only intraoperative com-
plication that occurred with a different frequency with MS
versus VATS (0.8% vs 5.3%, respectively; P  .004).
When the analysis was restricted to the centers that random-
ized to MS and VATS, there were no differences in the
percentage of patients without complications or in the rates
of specific complications.
Experience During the 30 Days After LVRS
The only statistically different postoperative complication
was the need to reoperate for air leak (MS, 2.2%; VATS,
5.9%; P  .05; Table 3), but when the analysis was re-
stricted to centers that randomized patients to both MS and
VATS, there was no difference in the frequency of need to
reoperate for air leak. However, in the randomized compar-
ison, failure to wean differed between groups (7.8%, MS;
0%, VATS; P  .03).
Table 4 shows the assessment of air leak at the comple-
tion of LVRS, the number of days with air leak for patients
who survived at least 30 days, and the percentage of patients
who died within 30 days of LVRS. Although there was a
higher incidence of air leak at the end of the VATS proce-
dure than at the end of the MS procedure (P  .01), there
was no difference between groups in the number of days
with air leak (P .74). Air leak on 7 or more days occurred
in 46% of MS patients, versus 49% of VATS patients (P 
y 2004
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domized patients to both MS and VATS, there was no
difference between groups in the presence of air leak at
closure or in the number of days with air leak.
Table 5 shows the number of days in the ICU, the
number of days on ventilator support for patients who
survived at least 30 days after LVRS, and the percentage of
patients who died within 30 days of LVRS. Days in the ICU
differed by approach (P  .001); patients in the MS group
required more ICU days after surgery than patients in the
VATS group. The difference in distributions was not statis-
tically significant when the analysis was restricted to the
centers that randomized patients to both MS and VATS.
Need for mechanical ventilation in the 30 days after LVRS
was similar for both groups; more than 80% of patients in
each treatment group required mechanical ventilation for 1
day or less.
Hospital length of stay was available from Medicare
claims for 343 MS patients and 146 VATS patients (489
patients total; 6 patients were enrolled in a
MedicareChoice plan or insured by non-Medicare insur-
ers, and claims for the LVRS procedure could not be located
for an additional 16 individuals). Length of hospital stay
was analyzed whether the stay ended in hospital discharge
or death. The length of hospital stay (mean  SD) was 17
 19 days for MS patients versus 14  9 days for VATS
patients (P  .06). The median length of stay was 10 days
for MS patients and 9 days for VATS patients (P  .01).
TABLE 2. Features of the LVRS procedure* (n  511)
Variable
Surgeon’s estimate of amount of right lung removed (%)
20
20-34
35-49
50
Surgeon’s estimate of amount of left lung removed (%)
20
20-34
35-49
50
Weight of right lung resected (g)
Weight of left lung resected (g)
LVRS, Lung volume reduction surgery; VATS, video-assisted thoracoscopic
diffusing capacity of lung for carbon monoxide; NETT, National Emphysem
*Patients with FEV1 20% predicted and either homogeneous emphysema
to LVRS who did not receive LVRS within NETT.
†P values for differences in means (t test) or homogeneity (Freeman-Halt
‡Randomized comparison of median sternatomy (n  77) with VATS (n 
test).When the comparison was restricted to the centers that
The Journal of Thoracicrandomized patients to both MS (75 patients) and VATS (67
patients), the length of hospital stay was 19  15 days for
MS patients versus 13  15 days for VATS patients (P 
.02), and the median length of stay was 15 days for MS
patients and 9 days for VATS patients (P  .001).
Residence
By 30 days after surgery, 70.5% of MS patients and 80.9%
of VATS patients were living independently (P  .02).
When the comparison was restricted to the centers that
randomized patients to MS and VATS, the difference in the
percentage of patients who were living independently was
greater (62.3%, MS; 87.3%, VATS; P .001). By 4 months
after randomization, the percentages were 87.5% and 90.8%
(P  .36), respectively, for the nonrandomized comparison
and 83.1% and 90.1% (P  .24), respectively, for the
randomized comparison.
Functional Outcomes
Histograms of the changes from postrehabilitation baseline
in exercise capacity, forced expiratory volume in 1 second
percentage of predicted, 6-minute walk distance, St
George’s Respiratory questionnaire, and Quality of Well-
Being Scale after 12 and 24 months of follow-up (measured
since randomization) are shown in Figure 1. Outcomes for
individual patients varied widely regardless of approach,
but the distributions of change were similar for both ap-
proaches. Similar results were observed when the analysis
Nonrandomized comparison
P value‡
an sternotomy
n  359)
VATS
(n  152) P value†
0.6% 0.0%
1.8% 78.0%
2.0% 18.7%
5.6% 3.3% .003 .25
0.6% 0.0%
5.0% 85.3%
6.3% 10.7%
8.2% 4.0% .001 .08
.0 30.8 62.8 51.8 .17 .18
.4 51.8 61.7 73.3 .14 .35
ry; FEV1, forced expiratory volume in 1 s; CT, computed tomography; DLCO,
atment Trial.
scan or DLCO 20% predicted were excluded, as were patients assigned
t).
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MS and VATS.
Costs
Costs were analyzed for the 489 patients for whom Medi-
care claims data were available (343 MS patients and 146
VATS patients) and are shown in Table 6. Mean hospital
and physician costs for the LVRS admission were $8207
less for the VATS group compared with the MS group (95%
confidence interval [CI] on difference, $917-$16,035; P 
.03). Mean total costs (medical and nonmedical) during the
6 months after surgery were $10,428 lower for the VATS
group (95% CI on difference, $9786-$109,062; P  .005).
When the comparison was restricted to the centers that
randomized patients to MS and VATS (75 MS patients and
67 VATS patients), mean hospital and physician costs for
the LVRS admission were $7138 less for the VATS group
TABLE 3. Complications* (n  511)
Complication
Median ste
(n  3
Intraoperative
None 93.0%
Hypotension 0.3%
Arrhythmia 1.7%
Hypoxemia 0.8%
Hypercarbia 0.8%
Cardiac arrest 0.3%
Uncontrolled air leak 0.8%
Other 3.3%
Postoperative
None 41.6%
Atrial fibrillation 2.5%
Arrhythmia 21.3%
Failure of early extubation 3.1%
Tracheostomy 9.2%
Failure to wean 6.1%
Reoperation for air leak 2.2%
Pulmonary embolus 0.6%
Readmission to ICU 11.4%
Mediastinitis 0.8%
Sternal debridement 0.8%
Pneumonia 20.1%
Urinary retention 4.2%
Epidural catheter complications 1.1%
Sepsis 2.0%
Readmission within 72 h after discharge 2.2%
VATS, Video-assisted thoracoscopic surgery; ICU, intensive care unit; FE
capacity of lung for carbon monoxide; LVRS, lung volume reduction surge
*Patients with FEV1 20% predicted and either homogeneous emphysema
to LVRS who did not receive LVRS within NETT. More than 1 complicatio
†P values for homogeneity (Fisher exact test).
‡Randomized comparison of median sternotomy (n  77) with VATS (n 
§The specified complication did not occur in either treatment group undecompared with the MS group (95% CI on difference, $5900-
1354 The Journal of Thoracic and Cardiovascular Surgery ● Ma$20,177; P  .28). Mean total costs during the 6 months
after surgery were $6500 lower for the VATS group (95%
CI on difference, $4295-$8,705; P  .001).
Differences Between Centers
All centers had similar percentages of patients dead by 30
days after surgery (P  .37) and similar percentages of
patients without postoperative complications (P  .51).
Discussion
This is the largest direct comparison of LVRS by MS and
VATS approaches, and it included a subset of patients for
whom the surgical approach was randomly assigned. We
found that the 2 approaches carry similar risks of 30-day,
90-day, and overall mortality; have similar complication
rates; and have similar changes in exercise capacity, lung
function, and general and disease-specific quality of life.
Nonrandomized comparison
P value‡
my VATS
(n  152) P value†
86.2% .02 .80
0.7% .51 .99
0% .19 .99
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2.0% .30 .68
0% .32 .99
4.0% .22 .35
3.3% .54 .35
rced expiratory volume in 1 s; CT, computed tomography; DLCO, diffusing
ETT, National Emphysema Treatment Trial.
scan or DLCO 20% predicted were excluded, as were patients assigned
ld be reported for a patient.
P values for homogeneity (Fisher exact test).
randomized comparison.rnoto
59)
V1, fo
ry; N
on CT
n cou
71):
r they 2004
1): P
atient
National Emphysema Treatment Trial Research Group General Thoracic Surgery
G
TSThe MS approach incurred slightly longer ICU and hospital
lengths of stay and greater costs.
Because LVRS is a palliative, elective procedure, one of
TABLE 5. Days in ICU and days on mechanical ventilation
Variable Median sternotomy
Days in ICU
Alive 30 d after LVRS
0-1 d in ICU 43.1%
2 d in ICU 15.3%
3-29 d in ICU 36.2%
30 d in ICU 2.3%
Dead within 30 d of LVRS 2.8%
No. of patients 354
Days on mechanical ventilation
Alive 30 d after LVRS
0 d on ventilator 76.2%
1 d on ventilator 6.4%
2-14 d on ventilator 6.2%
15-29 d on ventilator 7.6%
30 d on ventilator 0.8%
Dead within 30 d of LVRS 2.8%
No. of patients 357
ICU, Intensive care unit; VATS, video-assisted thoracoscopic surgery; LV
computed tomography; DLCO, diffusing capacity of lung for carbon monox
*Patients with FEV1 20% predicted and either homogeneous emphysema
to LVRS who did not receive LVRS within NETT.
†P values for homogeneity (Freeman-Halton test).
‡Randomized comparison of median sternotomy (n  77) to VATS (n  7
TABLE 4. Air leak at closure and in the 30 days after surg
Variable
Air leak at closure
None
Occasional bubble or pinhole stream
Intermediate stream of bubbles with respiratory variation
Large stream of nearly constant bubbles
No. of patients
Days with air leak in the 30 d after surgery
Alive 30 d after surgery
0 d with air leak
1-6 d with air leak
7-14 d with air leak
15-29 d with air leak
30 d with air leak
Dead within 30 d of surgery
No. of patients
VATS, Video-assisted thoracoscopic surgery; FEV1, forced expiratory volum
monoxide; LVRS, lung volume reduction surgery; NETT, National Emphyse
*Patients with FEV1 20% predicted and either homogeneous emphysema
to LVRS who did not receive LVRS within NETT.
†P values for homogeneity (Freeman-Halton test).
‡Randomized comparison of median sternotomy (n  77) with VATS (n 
§Data on air leak after closure were missing for 20 median sternotomy pthe greatest concerns was the mortality rate for the proce-
The Journal of Thoracicdure. Reported operative mortality rates were generally
3.5% to 10%, but some were as high as 19.1%.4-8,19,20
Moreover, on the basis of data for Medicare patients who
 511)
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TSFigure 1. Histograms of changes from postrehabilitation baseline in exercise capacity (maximum work), forced
expiratory volume in 1 second (FEV1) percentage predicted, 6-minute walk distance, St George’s Respiratory
Questionnaire, and Quality of Well-Being Scale after 12 and 24 months of follow-up (measured from randomization).
The category “Missing” includes patients too ill to complete the procedure and patients who refused to complete
the procedure but did not provide information about why they did not complete the procedure. For the Quality of
Well-Being Scale, patients who died were given a value of 0 on the questionnaire for the visit, and patients who
did not complete the questionnaire were assigned a value equal to one half the lowest score observed for the visit.
The P values for disparity in outcome distributions between the median sternotomy (MS) and video-assisted
thoracoscopy (VATS) groups were determined from Wilcoxon rank sum tests; the degree to which the bars are
shifted to the upper left of the chart indicates the degree of relative benefit of MS over VATS. The percentage
shown in each quadrant is the percentage of patients in the specified treatment group with change in the outcome
in that quadrant. Patients with FEV1 less than or equal to 20% predicted and either homogeneous emphysema or
diffusing capacity of the lung for carbon monoxide less than or equal to 20% of predicted were excluded, as were
patients assigned to LVRS who did not receive LVRS within NETT.1356 The Journal of Thoracic and Cardiovascular Surgery ● May 2004
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at 12 months.21 However, in this prospective multicenter
study, the NETT observed a 90-day mortality for LVRS of
5.9% for MS and 4.6% for VATS.
Postoperative morbidity after LVRS has been a source of
concern. The morbidity for the MS and VATS approaches
to LVRS showed very little difference. Although there was
a slight trend for higher 30-day mortality after MS than after
VATS, this was not statistically significant. The median
hospital length of stay was longer for MS than for VATS.
The rate of complications was low for both approaches and
was not statistically different.
Air leak lasting 7 or more days is the most commonly
reported complication after LVRS and occurs in approxi-
mately half of patients.4-8,19,20 The NETT data for air leak
are similar to published data. The VATS patients had a
higher incidence of air leak at closure than the MS patients;
this is presumably because intraoperative identification and
elimination of air leaks is more difficult for a VATS ap-
proach than for an MS approach. However, there was no
difference between the MS and VATS groups in the per-
centage of patients with air leak for 7 or more days.
The analysis of functional outcomes demonstrated only
slight differences between MS and VATS. The VATS pa-
tients achieved independent living after LVRS slightly ear-
lier than the MS patients (P .001). However, at 12 and 24
months after randomization, the functional outcomes were
essentially identical for MS and VATS.
The cost analysis demonstrated that patients who under-
went VATS had significantly lower costs for the initial
hospital stay. The lower costs likely reflect fewer ICU days
and a reduced overall length of stay for the VATS group.
Overall costs at 6 months were also lower for the VATS
group.
The results of this study must be interpreted in light of
TABLE 6. Costs* (n  489)
Variable
Median st
(n 
Cost for LVRS and associated hospital stay§
Mean  SD $38,557 
Median $23,
Total costs for 6 mo after LVRS (mean  SD) $61,481 
VATS, Video-assisted thoracoscopic surgery; FEV1, forced expiratory volum
monoxide; LVRS, lung volume reduction surgery; NETT, National Emphyse
*Patients with FEV1 20% predicted and either homogeneous emphysema
to LVRS who did not receive LVRS within NETT and 22 patients for whom
†P values for differences in means (t test).
‡Randomized comparison of median sternotomy (n  75) with VATS (n 
§Medicare reimbursements for hospitalization.
Includes all medical and related nonmedical costs incurred over the perthe use of randomization for only a portion (29%) of the
The Journal of Thoracicsample. Randomization was used at centers that were capa-
ble of offering and willing to offer both procedures. Some
surgeons felt comfortable with either procedure, whereas at
other centers, all of the procedures of a given type were
performed by an individual surgeon. In any case, we think
that it is important to present all of the NETT data that bear
on the question of MS versus VATS. The results demon-
strate the importance of randomization—a number of seem-
ingly significant differences in the nonrandomized compar-
isons disappeared in the randomized subset. This is not due
to the smaller sample size in the randomized comparison,
because the effect size diminished or disappeared in these
circumstances.
In conclusion, the data from the NETT show that com-
plication rates do not significantly differ for the 2 proce-
dures. Although the recovery seems to be earlier and the
costs less for the VATS approach, there is no difference
between the MS and VATS patients with respect to the
functional results at 12 and 24 months after randomization.
Patients with prior sternotomy or unilateral emphysema
were excluded from the NETT. In such patients, VATS may
be preferable. However, for patients without prior chest
operation and with bilateral emphysema, either approach
confers the same low risk of operative mortality and the
same opportunity for benefits. The choice of approach is a
matter of the surgeon’s preference and experience.
We thank Arthur Gelb, MD, Lakewood Regional Medical
Center, Lakewood, Calif.
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